Clinical Report: Alterations in Circulating Damage-Associated Molecular Patterns in Patients with Diabetic Foot Syndrome
Overview
This study identifies systemic alterations in circulating damage-associated molecular patterns (DAMPs) in patients with diabetic foot syndrome (DFS).
Background
Diabetic foot syndrome is a significant complication of diabetes, leading to increased amputation rates and severe infections. Understanding the molecular mechanisms underlying DFS is crucial for developing effective interventions. This study explores the role of DAMPs in the inflammatory processes associated with DFS.
Data Highlights
Proteomic analysis revealed differences in the abundance of multiple proteins associated with inflammation and stress in DFS patients compared to diabetic controls.
Key Findings
Identified proteins include serum amyloid A1, S100A8, and fibrinogen chains, which differ in abundance between DFS patients and controls.
Several DAMPs exhibited reproducible patterns across the studied groups, indicating a coordinated molecular response.
TLR4 inhibition in a murine model altered the abundance of circulating proteins, suggesting a link between innate immune signaling and DAMP profiles.
Findings support the hypothesis of systemic alterations in DAMP abundance in DFS.
Proteomics data are available via ProteomeXchange with identifier PXD073507.
Clinical Implications
The identification of specific DAMPs associated with DFS may guide future research.
Conclusion
The study provides evidence of systemic DAMP alterations in patients with diabetic foot syndrome.
by Elena Uyy, Viorel-Iulian Suica, Luminita Ivan, Raluca Maria Boteanu, Diana Valentina Uta, Elena Georgiana Bernea, Dragoş Eugen Georgescu, Ovidiu Chiriac, Maya Simionescu, Felicia Antohe
Manufacturers would be required to notify the FDA of GRAS determinations under a proposed rule, while HHS and USDA also submitted the first proposed federal definition of ultra-processed foods for final review.
Nearly 40% of patients initiated thyroid hormone therapy within 2 years of hemithyroidectomy, with higher preoperative thyroid‐stimulating hormone levels and thyroid cancer identifying those at greatest risk.
